The information contained on this page is intended
for US healthcare professionals only.  Patient siteFREE SAMPLES/COUPONS

The information contained on this page is intended
for US healthcare professionals only.  Patient siteFREE SAMPLES/COUPONS

VAZALORE® is heart protection with the stomach in mindTM

See our
DELIVERY MECHANISM

VAZALORE is specially designed to help
protect the stomach and deliver fast, predictable absorption and antiplatelet activity.1

VAZALORE’s drug delivery system employs a pH-dependent release mechanism that relies on chemical association of lipidic excipients with active pharmaceutical ingredients to selectively release them to targeted portions of the GI tract.

Preassociating the aspirin in VAZALORE to our pharmaceutical lipid prevents the aspirin from interacting with similar naturally occurring phospholipids in the stomach lining, helping to prevent local gastric injury.

Aspirin-lipid complex limiting contact with gastric mucosa

LIMITS DIRECT CONTACT

VAZALORE’s complex remains stable in the low pH of the stomach, limiting direct contact between aspirin and the gastric mucosa

Targeted delivery

Once the complex arrives in the duodenum, it dissociates in the higher-pH environment and aspirin is free to be absorbed
Aspirin-lipid complex in higher-pH environment of the duodenum
Aspirin and lipids are dissociated available for absorption

Fast, PREDICTABLE absorption

This drug delivery system is intended to predictably release aspirin in the duodenum to optimize absorption

Reassembles
during reflux

Even if reflux occurs and aspirin and lipidic excipients return to the stomach, they reassemble into the complex, limiting direct stomach contact, helping to reduce local GI injury

Aspirin-lipid complex re-assembled to limit contact with gastric mucosa

Reference:

  1. Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019;48(4):554-562.

Read VAZALORE 325 mg clinical results
 
 

Access VAZALORE resources
 
 

Opportunity for innovation in
aspirin delivery